Jin‐Yuan Shih - Concepedia

Author

Jin‐Yuan Shih

National Taiwan University Hospital ORCID

Also Known As

J SHIH, J Shih, J Y Shih, J. Shih, J. Y. Shih, J.-Y. Shih, J.Y. Shih, JIN-YUAN SHIH, Jin-Yuan Shih, Jin‐Yuan Shih

475

Publications

18K

Citations

H-Index

103

Concepts

All Affiliations

National Taiwan University Hospital National Taiwan University Dayeh University Far Eastern Memorial Hospital Taichung Veterans General Hospital

About

Jin‐Yuan Shih is an author at National Taiwan University Hospital specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	44	89	8.6K
2	Health Sciences	12	12	571
3	Engineering	3	3	1.6K
4	Public Health	2	2	198
5	Natural Sciences	1	1	74

Jin‐Yuan Shih

186

Publications

15.6K

Citations

H-Index

Page 1

	Year	Citations
<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib James Bean, Cameron Brennan, Jin‐Yuan Shih, Proceedings of the National Academy of Sciences Harbors Met AmplificationEngineeringPathologyTumor BiologyOncology	2007	1.6K
Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of <i>TWIST</i> Gene Expression Hui‐Wen Lo, Sheng-Chieh Hsu, Weiya Xia, Cancer Research	2007	625
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, The Lancet Oncology MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology	2019	594
Pretreatment Epidermal Growth Factor Receptor ( <i>EGFR</i> ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer Kang‐Yi Su, Hsuan‐Yu Chen, Ker-Chau Li, Journal of Clinical Oncology	2012	489
Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer Jenn‐Yu Wu, Chong‐Jen Yu, Yeun‐Chung Chang, Clinical Cancer Research	2011	461
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su, The Lancet Oncology Advanced Lung DiseaseMedicineLung AdenocarcinomaPathologyLux-lung 2	2012	402
Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry Oliver Gautschi, Julie Milia, Thomas Filleron, Journal of Clinical Oncology	2017	349
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study Antonio Passaro, Jing Wang, Yan Wang, Annals of Oncology	2023	347
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells Jen-Liang Su, Pan‐Chyr Yang, Jin‐Yuan Shih, Cancer Cell Tumor BiologyOncologyMedicineCancer Cell BiologyEpithelial-mesenchymal Interactions	2006	342
Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response Jenn‐Yu Wu, Shang‐Gin Wu, James Chih‐Hsin Yang, Clinical Cancer Research	2008	318

Page 1